Alnylam Pharmaceuticals (ALNY) Cash from Operations Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 158.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158.60% |
| Dec 31, 2025 | 272.78% |
| Sep 30, 2025 | 643.84% |
| Jun 30, 2025 | 25.43% |
| Mar 31, 2025 | -47.59% |
| Dec 31, 2024 | -217.71% |
| Sep 30, 2024 | -87.84% |
| Jun 30, 2024 | 310.49% |
| Mar 31, 2024 | 51.03% |
| Dec 31, 2023 | 77.42% |
| Sep 30, 2023 | 411.76% |
| Jun 30, 2023 | 51.97% |
| Mar 31, 2023 | 2.76% |
| Dec 31, 2022 | 12.10% |
| Sep 30, 2022 | 13.99% |
| Jun 30, 2022 | -0.79% |
| Mar 31, 2022 | 27.36% |
| Dec 31, 2021 | -21.92% |
| Sep 30, 2021 | -21.49% |
| Jun 30, 2021 | 9.96% |